0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Intellia Focuses on Pipeline Development Amid Stiff Competition [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company's co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. Two separate phase III studies are evaluating nex-z for treating transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) and hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR-CM. If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for nex-z. The phase III MAGNITUDE 2 study is actively screening patients with ATTRv-PN, with the first patient expected to be dosed shortly. The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Intellia Focuses on Pipeline Development Amid Stiff Competition [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company's co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in the deal for nex-z, REGN shares 25% of the development costs and commercial profits. Two separate phase III studies are evaluating nex-z for treating transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) and hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). The phase III MAGNITUDE study is evaluating the safety and efficacy of nex-z in patients with ATTR-CM. If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for nex-z. The phase III MAGNITUDE 2 study is actively screening patients with ATTRv-PN, with the first patient expected to be dosed shortly. The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS